Stock & Company Details
Equillium Inc $EQ
Price:
46,691,331
63M
$202M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-2.38
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
EQ technical indicators
Latest Equillium Inc (EQ) technical indicators as of 2026-06-30: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
64.63 5.0%
MACD:
0.16 8.3%
SMA 50:
$2.51 0.9%
SMA 200:
$1.73 0.4%
EMA 20:
$2.87 1.2%
Bollinger Bands:
3.22 / 2.60
Stochastic:
76.99 0.3%
ADX 14:
18.44 6.5%
ATR 14:
0.28 6.0%
CCI 20:
181.73 99.7%
OBV:
534.76M 0.8%
ROC 12:
13.88% 9.6%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Finance Bot
Ask your questions
Start by typing a question below.
